All In Biotech

Drug Trial Radar · NCT06782958

Safety, Tolerability, and Pharmacokinetics of FHND1002 Granules in Healthy Adults

A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of FHND1002 Granules After Single and Multiple Doses in Healthy Adult Volunteers

Last checked: Nov 19, 2026Latest source record: Jan 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

72

Planned (sponsor's estimate)

Start

Jul 5, 2024

Primary completion

Mar 3, 2025

Study completion Jun 5, 2025

Sponsor

Sponsor type
Industry
First posted
Jan 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of FHND1002 granules in healthy adult volunteers. The study will also assess how a high-fat meal affects the PK characteristics of FHND1002. The main questions this study aims to answer are: What are the safety and tolerability of FHND1002 granules when administered as single or multiple doses? What are the PK parameters of FHND1002, and what metabolites can be identified in humans? Participants will: Take FHND1002 granules or a placebo once daily, either as a single dose or for 7 consecutive days. Attend regular clinic visits for checkups, tests, and blood sample collection. Undergo assessments, including monitoring for adverse events, physical exams, vital signs, ECGs, and laboratory tests.

Conditions

  • Amyotrophic Lateral Sclerosis (ALS)

Interventions

  • 50mg FHND1002Drug

    Participants will receive a daily oral dose of FHND1002 granules (50 mg) ,administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.

  • 100mg FHND1002Drug

    Participants will receive a daily oral dose of FHND1002 granules (100 mg) , administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.

  • 150 mg FHND1002Drug

    Participants will receive a daily oral dose of FHND1002 granules (150 mg), administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.

  • 200 mg FHND1002(fasting)Drug

    Participants will receive a daily oral dose of FHND1002 granules (200 mg), administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.

  • 250mg FHND1002Drug

    Participants will receive a daily oral dose of FHND1002 granules (250 mg), administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.

  • 200mg FHND1002(postprandial)Drug

    Participants will receive a one-time dose (200 mg) under postprandial conditions

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Peak Plasma Concentration (Cmax)Time frame: 4 weeks
  2. Time to Peak Plasma Concentration (Tmax)Time frame: 4 weeks
  3. Area Under the Curve from 0 to the Last Quantifiable Time Point (AUClast)Time frame: 4 weeks
  4. Area Under the Curve Over the Dosing Interval (AUCτ)Time frame: 4 weeks
  5. Trough Concentration (Cmin)Time frame: 4 weeks
  6. Average Plasma Concentration (Cavg)Time frame: 4 weeks
  7. Accumulation Ratio (Rac)Time frame: 4 weeks
  8. Elimination Half-life (t1/2)Time frame: 4 weeks
  9. Area Under the Curve from 0 to Infinity (AUC0-inf)Time frame: 4 weeks
  10. Incidence of Adverse Events(AEs)Time frame: 7 weeks
  11. Incidence of Adverse Drug Reactions (ADRs)Time frame: 7 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The first hospital of Lanzhou University

    Lanzhou, Gansu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.